the extent of the experiment was explained to the patients and their family members, and written consents were obtained. Detailed clinical and laboratory features of the cases are shown in Table 1 .
Pathological study
Muscle samples were obtained from biceps muscles by open biopsy, frozen immediately in liquid nitrogen-cooled isopentane, and stored at -70℃ until used. Fresh frozen blocks of biopsied muscle were sectioned at 10 m thickness, processed for modified Gomori-trichrome (MGT), succinyl dehydrogenase (SDH), ATPase at pH 4.3, and cytochrome oxidase (COX), and were finally reviewed under light microscope. For electron microscopy, the samples were fixed with 2% glutaraldehyde and embedded in epoxy resin according to the standard procedure. Semithin 1 m thick resin sections were stained with toluidine blue for light microscopy. Ultrathin sections (60 nm thick) were cut with diamond knives on an ultramicrotome (REICHERT SUPER-NOVA TM , Leica, Germany), double stained with uranyl acetate and lead citrate, and examined under electron microscope (GEM1200EX-2 TM , JEOL, Japan).
PCR-RFLP analysis
Since about 80% of the reported cases are caused by A3243G transition (5), 10% by T3271C transition (6) and rarely by T3291C (7) and A3260G (8) of the mtDNA, the PCR-RFLP analysis was designed to detect A3243G, T3271C, and T3291C in MELAS cases (Table 2, 3). In MERRF, more than 90% of the cases have A8344G muta-tion (9) and other reported cases also cluster at tRNA Lys gene (T8356C (10), G8363A (11)). So, in cases with MERRF, the PCR-RFLP was designed to detect A8344G, T8356C, and G8363A mutations (Table 2, 3).
The DNA was extracted from the whole blood and muscle samples as described previously (12, 13) . Eppendorf Mastercycler 5330 (Eppendorf Co., U.S.A.) machine was used for PCR. The total volume of PCR reaction was 25.0 L, which consists of 2.5 L of ×10 reaction buffer, 2.0 L of 10 mN dNTPs, 2.5 L of each primers, 0.2 L of Ex Taq polymerase (TaKaRa, Japan), 1 L of DNA template, and 14.3 L of distilled water. The primers, thermal cycling conditions and resultant size of the PCR products are summarized in Table 2 The PCR product was then purified with MicroSpin TM S-400 HR Column (Amersham Pharmacia Biotech, U.K.), and the sequencing reaction was performed using BigDye TM Terminator Cycle sequencing kit (PE Applied Biosystems, U.S.A.). The total volume of the reaction was 20 L, which includes 8 L of BigDye Terminator (BDT), 2 L of primers, and 8 L of purified PCR product. The thermal cycling conditions were initiation at 96℃ for 10 sec and 25 cycles of denaturation at 96℃ for 10 sec, annealing at 50℃ for 5 sec, and extension at 60℃ for 4 min. Then, the product was purified with MicroSpin TM S-200 column (Amersham Pharmacia Biotech, U.K.) and analyzed by electrophoresis in 1% agarose. The automated sequencing was performed with ABI Prism 377 (PE Applied Biosystems, U.S.A.). Two microliters of loading buffer was added to the product, denatured at 95℃ 
RESULTS

Histochemical study
The proportion of RRFs judged by SDH stain was 15% and 12% in cases with MELAS (cases I and II) and 5% and 1% in cases with MERRF (cases III and IV). In each case with MELAS, strongly SDH-positive blood vessels (SSVs) were observed (Fig. 1) . In the cases with MELAS, some RRFs had focally increased COX activities (20% among RRFs in case I and 15% in case II), while many other RRFs showed decreas-ed or normal COX activities (Fig. 2) . In contrast, all RRFs showed either decreased or normal COX activities in the cases with MERRF, and no RRF with a focal increase in COX activity was observed (Fig. 3) .
PCR-RFLP and sequence analysis of MELAS (cases I and II)
In DNA form the blood, no mutation was found in PCR-RFLP for A3243G, T3271C, and T3291C in each case. Also, automated sequencing for tRNA Leu Ser genes revealed normal sequences. However, in DNA from the muscle, treatment with the restriction enzyme ApaI showed an abnormal digestion pattern on PCR-RFLP and proved to have A3243G mutation on subsequent DNA sequencing (Fig. 4, 5) .
PCR-RFLP and sequence analysis of MERRF (cases III and IV)
In each case, PCR-RFLP analysis with both blood and muscle DNA samples revealed an abnormal BglI digestion pattern and were finally confirmed to have an A8344G mutation (Fig. 6, 7) . The abnormal bands from muscle samples were clearer than those from venous blood on electrophoresis, suggesting there is a heavier mutant load in the muscle than in the blood. Among family members of case IV, an (Fig. 6 ).
DISCUSSION
The RRF is a pathological marker for the mitochondrial disease, which is most readily identified by SDH stain on frozen muscle biopsy, and represents proliferation of the abnormal mitochondria in muscle fibers. It is well known that the amount of the mutant mtDNA in RRF is bigger than that of non-RRF muscle fibers in patients with mitochondrial myopathies. However, the exact mechanism that determines the amount of the mutant load in each muscle fiber is not known (19, 20) .
The COX activity in muscle fibers is determined by the functional expression of the COX subunits in the mitochondrial inner membrane and thus, roughly correlates to the amount of the normal mtDNA. Because type I muscle fibers normally have more mitochondria than type II fibers, they show relatively increased COX activity than type II fibers on histochemical stain and appear as dark brown color while type II fibers stain light brown. Although the RRFs in mitochondrial myopathies have increased number of mitochondria, they are functionally abnormal harboring mutant mtDNA. Thus many of RRFs show decreased or loss of COX activities depending on the amount of mutant mtDNA they have (21) . Interestingly, the COX activity of RRFs in MELAS is known to be different from that of MERRF, and our study also showed differential staining patterns of MELAS and MERRF (22) . This finding is most likely caused by the differences in the expression of the COX subunit, and could be regarded as the secondary change resulting from a different pathogenetic mechanism between MELAS and MERRF. One of the important facts on COX immunohistochemistry is that the reduced or loss of COX activity does not necessarily mean the presence of mtDNA mutation. Because COX is encoded by three mitochondrial (COX I, II, and III) and nine nuclear genes (COX IV, Va, Vb, VIa, VIb, Vic, VIIa, VIIb, VIIc and VIII), its activity also can be altered by the (23, 24) . In this regard, the results of a recent study on the immunohistochemistry using COX subunits is noteworthy, where they found selective loss or reduction of COX I and II subunit activities in patients with known mtDNA mutations, while reduced staining of all subunits were observed in patients with probable nuclear DNA defects (25) . Thus, this technique would be useful for the differentiation of mitochondrial disease either into mtDNA defect or nuclear DNA defect, although further study seems to be needed in order to confirm its usefulness. The SSV is another important histological finding uniquely seen in MELAS (26) . The presence of SSV represents the affection of the vascular smooth muscle cells in MELAS and thought to be responsible for the stroke-like episode in this disease (26) .
The A3243G mtDNA mutation in MELAS was first reported by Goto et al. in 1990 (5) , and is responsible for about 80% of the cases. Until now, most of the known MELAS mutations are concentrated on the tRNA Leu (UUR) gene, even though there are some case reports affecting other genes in mtDNA (14) (15) (16) (17) (18) . Same frequencies of common MELAS mutations also seem to apply among Korean patients with MELAS, because 7 patients with A3243G mutation and one with T3271C out of 10 patients with MELAS had been identified in a study using blood sample (27) .
In our cases of MELAS, the mutation was not found from the blood DNA samples, but from the muscle samples. Thus, it is assumed that an exclusion of the MELAS mutation with a blood sample in clinically suspected cases could mislead the diagnosis. According to a report, the A3243G MELAS mutation can be found in about 50% of the cases when blood samples are used for PCR-RFLP (28) . This is thought to be the result of the rapidly replicating ability of the blood cells, which will gradually eliminate the leukocytes with a higher mutation load (28) . Interestingly, the A3243G mutations also have been found among different clinical phenotypes, including maternally inherited diabetes mellitus and deafness (MIDD) (29) , progressive external ophthalmoplegia (PEO) (30) , mitochondrial myopathy (31), and Leigh syndrome (32) . Also, there is a report documenting the different mutant mtDNA ratio among different phenotypes of the A3243G mutation, suggesting the clinical phenotypes may be determined by the mutant load (33) . The mtDNA mutations causing MERRF are known to be more homogenous than in MELAS. The A8344G mutation, first reported by Shoffner et al. (9) , is responsible for more than 90% of the cases of MERRF, and the T8356C (10) and G8363A (11) mutations were found in the rest of the cases. Also, in Korea, all of the molecular genetically confirmed cases had A8344G mutations (34, 35) . Thus, the MERRF mutations are concentrated exclusively on the tRNA Lys gene so far. Both of our MERRF cases clearly had a family history of maternal inheritance pattern typical of mitochondrial disorders, and the T8344C mutations were found both in PCR-RFLP and automated sequencing targeted for the tRNA Lys gene. Also, the mutations were readily identifiable in blood samples although the amount of the mutant DNA is less in blood samples than in muscle samples. Unlike the MELAS, there is a clear relationship in the amount of mutation between muscle tissue and blood cells in MERRF and this may represent the different pathogenetic mechanism between them (36, 37). In case IV, PCR-RFLP for family members revealed the same mutation in an asymptomatic sister. According to Larsson et al., the same mtDNA mutations are found in a half of the siblings when the amount of the mutant DNA of the mother is 10-33%, and all the siblings will have the mutation when the amount of maternal mutant DNA is 43-73% in MERRF (36) . The mother of case IV reportedly was unambulatory because of a profound muscle weakness when she was alive, and so, it is assumed that the amount of mutant DNA should be big enough to inherit the disease to some of her siblings, according to the "bottle neck hypothesis" in mtDNA segregation (37, 38) . The A8344G MERRF mutation is located at the T C loop of the tRNA Lys gene, and different phenotypes have been reported as in A3243G MELAS mutation (39, 40) . The A8344G mutation in the tRNA Lys gene affects the translation of lysine, and thus, produce the defect in protein synthesis (ex. ND5) (41) . Following the gene dosage effect, the symptoms tend to be more severe when there is a heavier mutant load in MERRF (42).
In conclusion, both MELAS and MERRF are caused by point mutations of the tRNA gene of the mitochondrial genome and have some common clinical findings despite many different aspects. Careful histochemical evaluation using frozen muscle tissue is important for the confirmation, differentiation and characterization of the mitochondrial diseases. In addition, the muscle tissue is essential for the molecular biological diagnosis and research of the mitochondrial diseases. 
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